NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Immunovant, Inc. (IMVT) Stock Analysis

Immunovant, Inc. (IMVT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IMVT

$39.25

+$0.13 (+0.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMVT with… →

IMVT Key Statistics

As of Sep 4, 2026
Trading
Open
$39.44
Previous Close
$39.12
Day's Range
38.73–39.73
52-Week Range
14.58–45.42
Volume
765.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.81
Valuation
Market Cap
$8.11B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.81
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$505.61M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
206.55M
1-Year Return
+143.49%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
1.27M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMVT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+54.41%
2025+2.62%
2024−41.21%
2023+137.35%
2022+108.33%
2021−81.55%
2020+191.05%
2019 (partial year)+59.50%

As of September 4, 2026.

IMVT Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$505.61M—
2024$0.00−$413.84M—
2023$0.00−$259.34M—
2022$0.00−$210.96M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$532.90M−$505.61M—
2024$0.00—−$438.15M−$413.84M—
2023$0.00—−$270.21M−$259.34M—
2022$0.00—−$208.28M−$210.96M—

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

IMVT Valuation vs Biotechnology Median

Median of 656 stocks
MetricIMVTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Immunovant, Inc. (IMVT) at $8.11B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 315 employees.

The 52-week range on file runs from $14.58 to $45.42. The most recent close on file for IMVT is $39.25, dated September 4, 2026. That is +$0.13 (+0.33%) against the previous close. The latest close sits 169.2% above that 52-week low.

Financial Health

In fiscal 2025, Immunovant, Inc. reported revenue of $0.00. The same year closed with a net loss of $505.61M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −2.81.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +143.49%. Measured over 5 years, that is +34.22% a year compounded. The reported beta is 0.81. Annualized volatility over the trailing 7 years is 76.09%.

Growth & Income

The record shows no dividend for IMVT.

2026 is still running; the price is +54.41% year to date. Across the complete calendar years on file, 2020 returned +191.05% and 2021 returned −81.55%. Of the 6 complete calendar years on file, 4 finished higher.

Peer Comparison

Immunovant, Inc. (IMVT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immunovant, Inc. IMVT $8.11B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Immunovant, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Visit website →